Literature DB >> 14581493

Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction.

Jackie D Corbin1, Sharron H Francis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14581493     DOI： 10.1002/j.1939-4640.2003.tb02744.x

Source DB:  PubMed          Journal:  J Androl        ISSN： 0196-3635


× No keyword cloud information.
  10 in total

1.  Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.

Authors:  Puneeta Tandon; Irteza Inayat; Michael Tal; Marcelo Spector; Martha Shea; Roberto J Groszmann; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-06       Impact factor: 11.382

2.  Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.

Authors:  Anthony H Chavez; K Scott Coffield; M Hasan Rajab; Chanhee Jo
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

Review 3.  Regulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potential.

Authors:  He Huang; Hu Wang; Maria E Figueiredo-Pereira
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

4.  PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.

Authors:  Jun-Jiang Chen; Yue-Li Sun; Amit K Tiwari; Zhi-Jie Xiao; Kamlesh Sodani; Dong-Hua Yang; Saraubh G Vispute; Wen-Qi Jiang; Si-Dong Chen; Zhe-Sheng Chen
Journal:  Cancer Sci       Date:  2012-07-06       Impact factor: 6.716

5.  The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.

Authors:  Pei-Rong Ding; Amit K Tiwari; Shinobu Ohnuma; Jeferson W K K Lee; Xin An; Chun-Ling Dai; Qi-Si Lu; Satyakam Singh; Dong-Hua Yang; Tanaji T Talele; Suresh V Ambudkar; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

Review 6.  Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.

Authors:  C Corinaldesi; L Di Luigi; A Lenzi; C Crescioli
Journal:  J Endocrinol Invest       Date:  2015-06-28       Impact factor: 4.256

7.  Iridoids and Amino Acid Derivatives from the Paraguayan Crude Drug Adenocalymma marginatum (ysypó hû).

Authors:  Guillermo Schmeda-Hirschmann; Alberto Burgos-Edwards; Felipe Jiménez-Aspee; Daniel Mieres-Castro; Cristina Theoduloz; Lisa Pormetter; Ramon Fogel; Claudia Céspedes; Nelida Soria; Sintya Valdez
Journal:  Molecules       Date:  2020-01-01       Impact factor: 4.411

Review 8.  Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.

Authors:  Rishil J Kathawala; Yi-Jun Wang; Charles R Ashby; Zhe-Sheng Chen
Journal:  Chin J Cancer       Date:  2013-10-09

Review 9.  The molecular targets of approved treatments for pulmonary arterial hypertension.

Authors:  Marc Humbert; Hossein-Ardeschir Ghofrani
Journal:  Thorax       Date:  2015-07-28       Impact factor: 9.139

Review 10.  Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.

Authors:  José L Sánchez-Gloria; Horacio Osorio-Alonso; Abraham S Arellano-Buendía; Roxana Carbó; Adrián Hernández-Díazcouder; Carlos A Guzmán-Martín; Ivan Rubio-Gayosso; Fausto Sánchez-Muñoz
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.